Navitoclax
Recurrent Malignant Solid Neoplasm
National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
76 Active assets in the Recurrent Malignant Solid Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | BB |
Crizotinib M.D. Anderson Cancer Center | Phase 2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | B |
Epirubicin University of California, Davis | Phase 2 | B |
Cyclophosphamide Anusha Kalbasi | Phase 2 | B |
View all 50 →
Same molecule, other indications
Navitoclax is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →